Outcome of Mycobacterium tuberculosis and Toll-like receptor interaction: Immune response or immune evasion?

Immunology and Cell Biology

Volumn 92, Issue 9, 2014, Pages 741-746

  Saraav, Iti ^a   Singh, Swati ^a   Sharma, Sadhna ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; HOST; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; INNATE IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN FUNCTION; REVIEW; TUBERCULOSIS; ANIMAL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MACROPHAGE;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; TOLL-LIKE RECEPTORS; TUBERCULOSIS;

EID: 84908160848     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.52     Document Type: Review

References (89)

1. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
2. Fallman M, Andersson R , Andersson T. Signaling properties of CR3 (CD11b/CD18) and CR1 (CD35) in relation to phagocytosis of complement-opsonized particles. J Immunol 1993; 151: 330-338.
3. Ingalls RR, Golenbock DT. CD 11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med 1995; 181: 1473-1479.
4. Ezekowitz RA, Sastry K, Bailly P, Warner A. Molecular characterization of the human macropha ge mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med 1990; 172: 1785-1794.
5. Means TK, Lien E, Yoshimura A, Wang S, Golenbock DT, Fenton MJ. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol 1999; 163: 6748-6755.
6. Stenger S, Modlin RL. Control of Mycobacterium tuberculosis through mammalian Toll-like receptors. Curr Opin Immunol 2002; 14: 452-457.
7. Heldwein KA, Fenton MJ. The role of Toll-like receptors in immunity against mycobacterial infection. Microbes Infect 2002; 4: 937-944.
8. Jo EK. Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs. Curr Opin Infect Dis 2008; 21: 279-286.
9. Medzhitov R, Preston-Hurlburt P, Janeway Jr. CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-397.
10. Krutzik SR, Modlin RL. The role of Toll-like receptors in combating mycobacteria. Semin Immunol 2004; 16: 35-41.
11. Ben-Ali M,Barbouche MR,Bousnina S,Ch abbou A,Dellagi K. Toll-like receptor 2 Arg677Trp polymorphism is associated with susceptibility to tuberculosis in Tunisian patients Clin Diagn Lab Immunol 2004, 11, 625-626.
12. Ogus AC, Yoldas B, Ozdemir T, Uguz A, Olcen S, Keser I et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004; 23: 219-223.
13. Singh S, Sara av I, Sharma S. Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis. Vaccine 2013; 32: 712-716.
14. Hernandez-Pando R, Orozco H, Arriaga K, Sampieri A, Larriva-Sahd J, Madrid-Marina V. Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-Alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis. Immunology 1997; 90: 607-617.
15. Law K, Weiden M, Harkin T, Tchou-Wong K, Chi C, Rom WN. Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-Alpha by bronchoalveolar cells la vaged from involved sites in pulmonary tuberculosis. AmJ Respir Crit Care Med 1996; 153: 799-804.
16. Giacomini E, Iona E, Ferroni L, Miettinen M, Fattorini L, Orefici G et al. Infecti on of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J Immunol 2001; 166: 7033-7041.
17. Sharma S, Bose M. Role of cytokines in immune response to pulmonary tuberculosis. Asian Pac J Allergy Immunol 2001; 19: 213-219.
18. Chan ED, Chan J, Schluger NW. What is the role of nitric oxide in murine and hu man host defense against tuberculosis?Current knowledge. Am J Respir Cell Mol Biol 2001; 25: 606-612.
19. Bose M, Farnia P, Sharma S, Chattopadhya D, Saha K. Nitric oxide dependent killing of Mycobacterium tuberculosis by human mononuclear phagocytes from patients with active tuberculosis. Int J Immunopathol Pharmacol 1999; 12: 69-79.
20. Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291: 1544-15 47.
21. Drennan MB, Nicolle D, Quesniaux VJ, Jacobs M, Allie N, Mpagi J et al. Toll-like receptor 2-deficient mice succum b to Mycobacterium tuberculosis infection. Am J Pathol 2004; 164: 49-57.
22. Sharma S, Sharma M, Roy S, Kumar P, Bose M. Mycobacterium tuberculosis induces high production of nitric oxide in c oordination with production of tumour necrosis factor-Alpha in patients with fresh active tuberculosis but not in MDR tuberculosis. Immunol Cell Biol 2004; 82: 377-382.
23. Bulut Y, Faure E, Thomas L, Equils O, Arditi M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecu les in Toll-like receptor 2 signaling. J Immunol 2001; 167: 987-994.
24. Quesniaux V, Fremond C, Jacobs M, Parida S, Nicolle D, Yeremeev V et al. Toll-like receptor pathways in the immu ne responses to mycobacteria. Microbes Infect 2004; 6: 946-959.
25. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in medi ating optimal resistance to Mycobacterium tuberculosis. J Exp Med 2005; 202: 1715-1724.
26. Reiling N, Holscher C, Fehrenbach A, Kroger S, Kirschning CJ, Goyert S et al. Cutting edge: Toll-like receptor (TLR)2-And TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol 2002; 169: 3480-3484.
27. Ahmad S. Pathogenesis, immunology, an d diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immunol 2011; 2011: 814943.
28. Harding CV, Boom WH. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev Microbiol 2010; 8: 296-307.
29. Gupta A, Kaul A, Tsolaki AG, Kishore U, Bhakta S. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 2012; 217: 363-374.
30. Bell JK, Mullen GED, Leifer CA, Mazzoni A, Davies DR, Segal DM. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003; 24: 528-533.
31. Dolan J, Walshe K, Alsbury S, Hokamp K, O'Keeffe S, Okafuji T et al. The extracellular leucine-rich repeat superfamily; a comparative survey and analysis of evolutionary relat ionships and expression patterns. BMC Genomics 2007; 8: 320.
32. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR et al. Host defense mechanisms triggered by mi crobial lipoproteins through toll-like receptors. Science 1999; 285: 732-736.
33. Jones BW,Heldwein KA,Means TK,Saukkonen JJ,Fenton MJ. Differential roles of Toll-like receptors in the eli citation of proinflammatory responses by macrophages Ann Rheum Dis 2001, 60(Suppl 3): iii6-12.
34. Means TK, Jones BW, Schromm AB, Shurtleff BA, Smith JA, Keane J et al. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol 20 01; 166: 4074-4082.
35. Bowdish DM, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S, Leifer CA et al. MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial treh alose dimycolate and Mycobacterium tuberculosis. PLoS Pathog 2009; 5: e1000474.
36. Pitarque S, Larrouy-Maumus G, Payre B, Jackson M, Puzo G, Nigou J. The immunomodulatory lipoglycans, lipoarab inomannan and lipomannan, are exposed at the mycobacterial cell surface. Tuberculosis (Edinb) 2008; 88: 560-565.
37. Noss EH, Pai RK, Sellati TJ, Radolf JD, Belisle J, Golenbock DT et al. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J Immunol 2001; 167: 910-918.
38. Bulut Y, Michel sen KS, Hayrapetian L, Naiki Y, Spallek R, Singh M et al. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J Biol Chem 2005; 280: 209 61-20967.
39. Jung SB, Yang CS, Lee JS, Shin AR, Jung SS, Son JW et al. The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-Activated protein kinase pathway and release of proinfl ammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. Infect Immun 2006; 74: 2686-2696.
40. Akira S, Yamamoto M, Takeda K. Role of adapters in Toll-like receptor signalling. Biochem Soc Trans 2003; 31: 637-642.
41. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
42. Premkumar V, Dey M, Dorn R, Raskin I. MyD88-dependent and independent pathways of Toll-like receptors are engaged in biological activity of Triptolide in ligand-stimulated macrophages. BMC Chem Biol 2010; 10: 3.
43. Sharma M, Sharma S, Roy S, Varma S, Bose M. Pulmonary epithelial cells are a source of interferon-gamma in response to Mycobacterium tuberculosis infection. Immunol Cell Biol 2007; 85: 229-237.
44. Mogues T, Goodrich ME, Ryan L, LaCourse R, North RJ. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2001; 193: 271-280.
45. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-2254.
46. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420: 329-333.
47. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003; 4: 1144-1150.
48. Scanga CA, Bafica A, Feng CG, Cheever AW, Hieny S, Sher A. MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infect Immun 2004; 72: 2400-2404.
49. Holscher C, Reiling N, Schaible UE, Holscher A, Bathmann C, Korbel D et al. Containment of aerogenic Mycobacterium tubercu losis infection in mice does not require MyD88 adaptor function for TLR2,-4 and-9. Eur J Immunol 2008; 38: 680-694.
50. Moss JE, Aliprantis AO, Zychlinsky A. The regulation of apoptosis by microbial pathogens. Int Rev Cytol 1999; 187: 203-259.
51. Nishimura J, Saiga H, Sato S, Okuyama M, Kayama H, Kuwata H et al. Potent antimycobacterial activity of mouse secretory leukocyte prot ease inhibitor. J Immunol 2008; 180: 4032-4039.
52. Gomez SA, Arguelles CL, Guerrieri D, Tateosian NL, Amiano NO, Slimovich R et al. Secretory leukocyte protease inhibitor: a secreted pattern recognition receptor for mycobacteria. Am J Respir Crit Care Med 2009; 179: 247-253.
53. Saiga H, Shimada Y, Takeda K. Innate immune effectors in mycobacterial infection. Clin Dev Immunol 2011; 2011: 347594.
54. Sonawane A,Santos JC,Mishra BB,Jena P,Progida C,Sorensen OE,et al. Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages Cell Microbiol 2011, 13, 1601-1617.
55. Sharma S, Sharma M, Bose M. Mycobacterium tuberculosis infection of human monocyte-derived macrophages leads to apoptosis of T cells. Immunol Cell Biol 2009; 87: 226-234.
56. Koul A, Herget T, Klebl B, Ullrich A. Interplay between mycobacteria and host signalling pathways. Nat Rev Microbiol 2004; 2: 189-202.
57. Fly nn JL, Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol 2003; 15: 450-455.
58. Miller BH, Fratti RA, Poschet JF, Timmins GS, Master SS, Bu rgos M et al. Mycobacteria inhibit nitric oxide synthase recruitment to phagosomes during macrophage infection. Infect Immun 2004; 72: 2872-2878.
59. Nigou J, Gilleron M, Rojas M, Garcia LF, Thurnher M, Puzo G. Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response. Microbes Infect 2002; 4: 945-953.
60. Blander JM, Medzhitov R. On regula tion of phagosome maturation and antigen presentation. Nat Immunol 2006; 7: 1029-1035.
61. Yoshida A, Inagawa H, Kohchi C, Nishizawa T, Soma G. The role of toll-like receptor 2 in survival str ategies of Mycobacterium tuberculosis in macrophage phagosomes. Anticancer Res 2009; 29: 907-910.
62. Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 2008; 3: 399-407.
63. Malik ZA, Denning GM, Kusner DJ. Inhibition of Ca(2+) signaling by Mycobacterium tu berculosis is associated with reduced phagosome-lysosome fusion and increased survival within human macrophages. J Exp Med 2000; 191: 287-302.
64. Vergne I, Chua J, Deretic V. Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2+ /calmodulin-PI3K hVPS34 cascade. J Exp Med 2003; 198: 653-659.
65. Vergne I, Chua J, Deretic V. Mycobacterium tuberculosis phagosome maturation arrest: selective targeting of PI3P-dependent membrane trafficking. Traffic 2003; 4: 600-606.
66. Fratti RA, Chua J, Deretic V. Induction of p38 mitogen-Activated protein kinase reduces early endosome autoantigen 1 (EEA1) recruitment to phagosomal membranes. J Biol Chem 2003; 278: 46961-46967.
67. Tse HM, Joseph y SI, Chan ED, Fouts D, Cooper AM. Activation of the mitogen-Activated protein kinase signaling pathway is instrumental in determining the ability of Mycobacterium avium to grow in murine macrophages. J Immunol 2002; 168: 825-833.
68. Noss EH, Harding CV, Boom WH. Mycobacterium tuberculosis inhibits MHC class II antigen processing in murine bone marrow macrophages. Cell Immunol 2000; 201: 63-74.
69. Flynn JL, Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol 2003; 15: 450-455.
70. Baena A, Porcelli SA. Evasion and subversion of antigen presentation by Mycobacterium tuberculosis. Tissue Antigens 2009; 74: 189-204.
71. Pennini ME, Liu Y, Yang J, Croniger CM, Boom WH, Harding CV. CCAAT/enhancerbinding protein beta and delta bin ding to CIITA promoters is associated with the inhibition of CIITA expression in response to Mycobacterium tuberculosis 19-kDa lipoprotein. J Immunol 2007; 179: 6910-6918.
72. Chang CH, Guerder S, Hong SC, van Ewijk W, Flavell RA. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 1996; 4: 167-178.
73. Repique CJ, Li A, Bric key WJ, Ting JP, Collins FM, Morris SL. Susceptibility of mice deficient in the MHC class II transactivator to infection with Mycobacterium tuberculosis. Scand J Immunol 2003; 58: 15-22.
74. Pai R K, Pennini ME, Tobian AA, Canaday DH, Boom WH, Harding CV. Prolonged Toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in ma crophages. Infect Immun 2004; 72: 6603-6614.
75. Chang CH,Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation J Exp Med, 1995, 181, 765-767.
76. Majlessi L, Combaluzier B, Albrecht I, Garcia JE, Nouze C, Pieters J et al. Inhibition of phagosome maturation by mycobacteria does not interfere with presentation of mycobacterial antigens by MHC molecules. J Immunol 2007; 179: 1825-1833.
77. Ramachandra L, Smialek JL, Shank SS, Convery M, Boom WH, Harding CV. Phagosomal processing of Mycobacterium tuberculosis antigen 85B is modulated indepe ndently of mycobacterial viability and phagosome maturation. Infect Immun 2005; 73: 1097-1105.
78. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II e xpression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265: 106-109.
79. Fortune SM, Solache A, Jaeger A, Hill PJ, Belisle JT, Bloom BR et al. Mycobacte rium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and-independent mechanisms. J Immunol 2004; 172: 6272-6280.
80. Hirsch CS, Hussain R, Tooss i Z, Dawood G, Shahid F, Ellner JJ. Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci USA 1996; 93: 3193-3198.
81. Shi S, Nathan C, Schnappinger D, Drenkow J, Fuortes M, Block E et al. MyD88 primes macrophages for full-scale activation by interferon-gamma yet mediates few responses to Mycobacterium tu berculosis. J Exp Med 2003; 198: 987-997.
82. Gehring AJ, Dobos KM, Belisle JT, Harding CV, Boom WH. Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macroph age class II MHC antigen processing. J Immunol 2004; 173: 2660-2668.
83. Pecora ND, Gehring AJ, Canaday DH, Boom WH, Harding CV. Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR 2 that regulates innate immunity and APC function. J Immunol 2006; 177: 422-429.
84. Gilleron M, Nigou J, Nicolle D, Quesniaux V, Puzo G. The acylation state of mycobacterial lipomannans modul ates innate immunity response through toll-like receptor 2. Chem Biol 2006; 13: 39-47.
85. Nigou J, Vasselon T, Ray A, Constant P, Gilleron M, Besra GS et al. Mannan chain length contr ols lipoglycans signaling via and binding to TLR2. J Immunol 2008; 180: 6696-6702.
86. Wolf AJ, Linas B, Trevejo-Nunez GJ, Kincaid E, Tamura T, Takatsu K et al. Mycobacterium tuberculo sis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007; 179: 2509-2519.
87. Hava DL, van der Wel N, Cohen N, Dascher CC, Houben D, Leon L et al. Evasion of peptide, but not lipid antigen presentation, through pathogen-induced dendritic cell maturation. Proc Natl Acad Sci USA 2008; 105: 11281-11286.
88. Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, Appelmelk B et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003; 197: 7-17.
89. Simmons DP, Canaday DH, Liu Y, Li Q, Huang A, Boom WH et al. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J Immunol 2010; 185: 2405-2415.